Gyre Therapeutics (GYRE) Income from Continuing Operations (2010 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Income from Continuing Operations of 9858000.0 for Q1 2026, down 364.01% year-over-year from 3734000.0 in Q1 2025, and down 6339.24% quarter-over-quarter from 158000.0 in Q4 2025.
Powered by 
Analysis
Gyre Therapeutics (GYRE) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Income from Continuing Operations for 17 consecutive years, with 9858000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 364.01% year-over-year to 9858000.0; the TTM figure through Mar 2026 stood at 2188000.0 (down 118.71% YoY), while the FY2025 annual figure was 11404000.0, down 36.28% from the prior year.
- Income from Continuing Operations eased to 9858000.0 in Q1 2026 per GYRE's latest filing, from 158000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 51632000.0 in Q2 2022 and bottomed at 100977000.0 in Q4 2023.
- Historically, Income from Continuing Operations has averaged 3683058.82 across 5 years, with a median of 2856000.0 in 2024.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations surged 325.48% — and 2026, when it plunged 364.01%.
- Gyre Therapeutics' Income from Continuing Operations stood at 28788000.0 in 2022, then slumped by 250.76% to 100977000.0 in 2023, then jumped by 100.56% to 569000.0 in 2024, then plunged by 72.23% to 158000.0 in 2025, then sank by 6339.24% to 9858000.0 in 2026.
- Business Quant data shows GYRE's Income from Continuing Operations at 9858000.0 in Q1 2026, 158000.0 in Q4 2025, and 5936000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Gyre Therapeutics | 681.32 Mn | 623.92 Mn | 26.90 Mn | -14.27 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -14.27 Mn |
| Mar 31, 2026 | -9.86 Mn |
| Dec 31, 2025 | 2.72 Mn |
| Sep 30, 2025 | 5.94 Mn |
| Jun 30, 2025 | -2.24 Mn |
| Mar 31, 2025 | 3.73 Mn |
| Dec 31, 2024 | -433,000.00 |
| Sep 30, 2024 | 2.86 Mn |
| Jun 30, 2024 | 4.54 Mn |
| Mar 31, 2024 | 9.94 Mn |
| Dec 31, 2023 | -101.81 Mn |
| Sep 30, 2023 | 7.51 Mn |
| Jun 30, 2023 | 3.77 Mn |
| Mar 31, 2023 | 4.22 Mn |
| Dec 31, 2022 | -28.79 Mn |
| Sep 30, 2022 | -4.88 Mn |
| Jun 30, 2022 | 51.63 Mn |
| Mar 31, 2022 | -14.54 Mn |
| Dec 31, 2021 | -20.31 Mn |
| Sep 30, 2021 | -25.24 Mn |